Subject: chromogranin A
Subject: ELISA
Subject: octreotide therapy
Year: 2021
Type: Article
Title: Serum chromogranin-A levels in neuroendocrine neoplasms as prognostic marker in correlation with the clinical course of the disease and the influence of octreotid therapy
Author: Jovanovikj, Rubens
Author: Kostadinova Kunovska, Slavica
Author: Krsteska, Blagica
Author: Bogdanovska Todorovska, Magdalena
Author: Komina, Selim
Author: Zdravkovski, Panche
Author: Ilievski, Boro
Author: Janevska, Vesna
Author: Spasevska, Liljana
Author: Mitreski, Nenad
Author: Grozdanovska, Biljana
Author: Kostovski, Ognen
Author: Antovic, Svetozar
Author: Grivcheva Stardelova, Kalina
Author: Petrushevska, Gordana
Abstract: Introduction. Neuroendocrine neplasms (NEN) arise from neuroedocrine cells in various tissues and organs, have diverse biological behavior and express neuroendocrine markers synaptophysin and chromogranin A (CgA). Aim of the study. The aim of this study was to correlate the serum CgA levels before and after surgical and/or oncological treatment with octreotide and to determine the prognostic value of CgA variations during the follow-up. Material and methods. We used ELISA to analyze 699 serum samples from 410 patients during 9 years, due to carcinoid syndrome, benign neuroendocrine tumor (NET), localized neuroendocrine carcinoma (NEC) and patients with metastatic NEC (MS). Data from hospital databases were used for follow-up of 60 patients, divided into responders and non-responders, regarding their response to therapy. Results. The mean serum CgA value in 410 analyzed patients was by 3.47-fold increase compared to the maximal reference values. The highest increase was measured in patients with NEC/MS, with mean 12.94-fold increase, followed by patients with localized NECs, with mean 4.57. During follow-up, CgA values were reduced, with a significant difference between the groups of responders and non-responders. Conclusions. Reduction of the CgA level for at least 49.5% during the first 12 months after therapy was correlated with stable disease course, and serum CgA elevation or decrease less than 34% during the first 12 months after the therapy was correlated to unfavorable clinical course. Serum CgA levels are useful for the diagnosis of NENs and during the follow-up for detection of recurrence, disease progression and evaluation of the oncologic therapy response.
Publisher: Faculty of Medicine, University Ss. Cyril and Methodius in Skopje
Relation: Academic Medical Journal
Identifier: oai:repository.ukim.mk:20.500.12188/17783
Identifier: 2671-3853
Identifier: http://hdl.handle.net/20.500.12188/17783Identifier: 1
Identifier: 1
